Unibest

Pharmaceutical intermediates

Lemborexant Intermediates

4 pharmaceutical intermediates for Lemborexant. Indication: Sleep Initiation and Maintenance Disorders.

提交项目All intermediates

About Lemborexant

Originator
Eisai Inc
Indication
Sleep Initiation and Maintenance Disorders
Approved Date
04/07/2020
NCE Patent
04/07/2025
DS/DP
09/20/2031

Available intermediates

4 intermediates currently listed for Lemborexant. Request specifications, documentation or a quotation for any item below.

Lemborexant intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
(1S,5R)-1-(3-fluorophenyl)-3-oxabicyclo[3.1.0]hexan-2-one528587-70-4//
((1S,2R)-1-(3-fluorophenyl)cyclopropane-1,2-diyl)dimethanol1369767-20-3//
(1R,2S)-2-(3-fluorophenyl)-2-(hydroxymethyl)cyclopropyl]-methyl acetate1369768-29-5//
5-Pyrimidinol, 2,4-dimethyl- (9CI)412003-95-3//

Other programs under L

(LCZ696)LanifibranorLapatinibLarotrectinibLasmiditanLazertinib MesylateLenacapavir sodiumLenalidomide

Building toward Lemborexant?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →